Pub Date : 2025-07-01Epub Date: 2025-06-30DOI: 10.1080/17520363.2025.2523236
Lingling Chen, Jinxia Wang, Yanping Gao, Wenbo Xiu, Zuo Wang, Gao Zhang, An Li, Yang Chen, Bolin Deng, Fang Lu, Chong He, Lijuan Hu
Aim: To explore the relationship between plasma myeloperoxidase (MPO) and glaucoma, assessing the clinical utility of MPO in glaucoma.
Methods: A cross-sectional study involved 127 glaucoma patients and 106 healthy controls. Plasma MPO markers were quantified using enzyme-linked immunosorbent assay (ELISA), comparing levels between glaucoma patients and healthy controls, and analyzing plasma MPO across different glaucoma severity grades.
Results: In this study, we observed elevated plasma MPO levels in glaucoma patients (p < 0.001). After correcting for confounders such as age, sex, hypertension, and diabetes, plasma MPO remained independently associated with glaucoma (OR = 1.05, 95% CI: 1.04-1.07, p < 0.001). Plasma MPO may reflect the severity of glaucoma, with significant differences in plasma MPO observed between early and severe stages, but not in the moderate stages. In addition, elevated plasma MPO was associated with higher cup-to-disc ratios. ROC curve analysis demonstrated the validity of glaucoma markers in identifying early glaucoma from severe glaucoma (early versus severe: AUC = 0.633).
Conclusion: Elevated plasma MPO levels are independently associated with glaucoma risk, suggesting it might provide insight into disease pathogenesis.
{"title":"Analyzing the association between MPO levels and glaucoma severity.","authors":"Lingling Chen, Jinxia Wang, Yanping Gao, Wenbo Xiu, Zuo Wang, Gao Zhang, An Li, Yang Chen, Bolin Deng, Fang Lu, Chong He, Lijuan Hu","doi":"10.1080/17520363.2025.2523236","DOIUrl":"10.1080/17520363.2025.2523236","url":null,"abstract":"<p><strong>Aim: </strong>To explore the relationship between plasma myeloperoxidase (MPO) and glaucoma, assessing the clinical utility of MPO in glaucoma.</p><p><strong>Methods: </strong>A cross-sectional study involved 127 glaucoma patients and 106 healthy controls. Plasma MPO markers were quantified using enzyme-linked immunosorbent assay (ELISA), comparing levels between glaucoma patients and healthy controls, and analyzing plasma MPO across different glaucoma severity grades.</p><p><strong>Results: </strong>In this study, we observed elevated plasma MPO levels in glaucoma patients (<i>p</i> < 0.001). After correcting for confounders such as age, sex, hypertension, and diabetes, plasma MPO remained independently associated with glaucoma (OR = 1.05, 95% CI: 1.04-1.07, <i>p</i> < 0.001). Plasma MPO may reflect the severity of glaucoma, with significant differences in plasma MPO observed between early and severe stages, but not in the moderate stages. In addition, elevated plasma MPO was associated with higher cup-to-disc ratios. ROC curve analysis demonstrated the validity of glaucoma markers in identifying early glaucoma from severe glaucoma (early versus severe: AUC = 0.633).</p><p><strong>Conclusion: </strong>Elevated plasma MPO levels are independently associated with glaucoma risk, suggesting it might provide insight into disease pathogenesis.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"597-604"},"PeriodicalIF":1.9,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12258260/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144526464","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-05-26DOI: 10.1080/17520363.2025.2511473
Murat Karaçam, Azmican Kaya, Seda Tanyeri, Ali Furkan Tekatlı, Süleyman Çagan Efe, Cem Doğan, Gülümser Sevgin Halil, Sinan Cerşit, Barkın Kültürsay, Kaan Kırali, Rezzan Deniz Acar
Background: Corin is a cardiac protease that plays a role in transforming pro-natriuretic peptides into their active biological forms. This study aimed to investigate the relationship between serum corin levels and functional capacity in patients with advanced heart failure.
Methods: This cross-sectional study included 88 consecutive patients with LVEF (Left ventricular ejection fraction) <25% who were referred to the tertiary cardiovascular center. Serum corin levels were measured using ELISA (Enzyme-linked immunosorbent assay) prior to CPET (Cardiopulmonary exercise testing). Multivariable linear regression was used to assess the independent association between serum corin levels and peak VO₂ (Peak oxygen consumption).
Results: The mean age was 51.3 ± 12.2 years, and 86.4% were male. The mean peak VO₂ was 13.6 ± 3.99 mL/min/kg and the mean serum corin level was 1.7 ± 0.82 ng/mL. In multivariable analysis, serum corin level was an independent predictor of peak VO₂ (Coefficient: 1.206, 95% CI: 0.527-1.880, p = 0.0007).
Conclusion: Lower serum corin levels are independently associated with reduced functional capacity in advanced heart failure. Corin may serve as a valuable biomarker to complement CPET in clinical evaluation, risk stratification, and treatment planning.
{"title":"Association between serum corin levels and functional capacity in patients with advanced heart failure.","authors":"Murat Karaçam, Azmican Kaya, Seda Tanyeri, Ali Furkan Tekatlı, Süleyman Çagan Efe, Cem Doğan, Gülümser Sevgin Halil, Sinan Cerşit, Barkın Kültürsay, Kaan Kırali, Rezzan Deniz Acar","doi":"10.1080/17520363.2025.2511473","DOIUrl":"10.1080/17520363.2025.2511473","url":null,"abstract":"<p><strong>Background: </strong>Corin is a cardiac protease that plays a role in transforming pro-natriuretic peptides into their active biological forms. This study aimed to investigate the relationship between serum corin levels and functional capacity in patients with advanced heart failure.</p><p><strong>Methods: </strong>This cross-sectional study included 88 consecutive patients with LVEF (Left ventricular ejection fraction) <25% who were referred to the tertiary cardiovascular center. Serum corin levels were measured using ELISA (Enzyme-linked immunosorbent assay) prior to CPET (Cardiopulmonary exercise testing). Multivariable linear regression was used to assess the independent association between serum corin levels and peak VO₂ (Peak oxygen consumption).</p><p><strong>Results: </strong>The mean age was 51.3 ± 12.2 years, and 86.4% were male. The mean peak VO₂ was 13.6 ± 3.99 mL/min/kg and the mean serum corin level was 1.7 ± 0.82 ng/mL. In multivariable analysis, serum corin level was an independent predictor of peak VO₂ (Coefficient: 1.206, 95% CI: 0.527-1.880, <i>p</i> = 0.0007).</p><p><strong>Conclusion: </strong>Lower serum corin levels are independently associated with reduced functional capacity in advanced heart failure. Corin may serve as a valuable biomarker to complement CPET in clinical evaluation, risk stratification, and treatment planning.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"395-403"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143726/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144149230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Introduction: MicroRNA (miRNA) single nucleotide polymorphisms (miRNA-SNPs) have been associated with pediatric acute lymphoblastic leukemia (ALL). However, since the results of these individual studies have been inconsistent, we performed a meta-analysis to help establish a statistical significance for the association between miRNA-SNPs and pediatric ALL risk. We also analyzed whether they confer susceptibility across country-specific studies by using different genetic models.
Methods: Articles published from 2001 to 2023 were collected from PubMed and Google Scholar databases. Through MetaGenyo, the association between miRNA- SNPs and pediatric ALL risk was calculated by pooled odds ratio [ORs] and 95% CI. A subgroup analysis of pooled ORs in country-specific studies was also performed.
Results: Based on the inclusion and exclusion criteria, 14 studies were analyzed to extract data on miR146 rs2910164, miR-196a2 rs11614913, miR-612 rs12803915 and mir-499 rs3746444. While the pooled data analysis did not reveal any association, a subgroup analysis demonstrated country-specific differences in allele frequencies of all the four miRNAs in various genetic models, implying ethnicity-based risk.
Conclusion: Our results suggested that miRNA-SNPS can still be considered as a potential risk factor to be explored in more populations.
{"title":"Ethnicity modifies the association between microRNA single nucleotide polymorphisms and pediatric acute lymphoblastic leukemia risk: a meta-analysis.","authors":"Sharon Benita Antony, Julius Xavier Scott, Indhumathi Nagarthinam, Vinodhini Subramanian, Teena Koshy","doi":"10.1080/17520363.2025.2511466","DOIUrl":"10.1080/17520363.2025.2511466","url":null,"abstract":"<p><strong>Introduction: </strong>MicroRNA (miRNA) single nucleotide polymorphisms (miRNA-SNPs) have been associated with pediatric acute lymphoblastic leukemia (ALL). However, since the results of these individual studies have been inconsistent, we performed a meta-analysis to help establish a statistical significance for the association between miRNA-SNPs and pediatric ALL risk. We also analyzed whether they confer susceptibility across country-specific studies by using different genetic models.</p><p><strong>Methods: </strong>Articles published from 2001 to 2023 were collected from PubMed and Google Scholar databases. Through MetaGenyo, the association between miRNA- SNPs and pediatric ALL risk was calculated by pooled odds ratio [ORs] and 95% CI. A subgroup analysis of pooled ORs in country-specific studies was also performed.</p><p><strong>Results: </strong>Based on the inclusion and exclusion criteria, 14 studies were analyzed to extract data on miR146 rs2910164, miR-196a2 rs11614913, miR-612 rs12803915 and mir-499 rs3746444. While the pooled data analysis did not reveal any association, a subgroup analysis demonstrated country-specific differences in allele frequencies of all the four miRNAs in various genetic models, implying ethnicity-based risk.</p><p><strong>Conclusion: </strong>Our results suggested that miRNA-SNPS can still be considered as a potential risk factor to be explored in more populations.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"435-449"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140483/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172523","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-05-25DOI: 10.1080/17520363.2025.2511468
Çağlayan Biçer, Fatih Akkuş, Yusuf Dal
Objective: This retrospective study evaluated the predictive power of a new marker for pre-eclampsia (PE), the neutrophil percentage/albumin ratio (NPAR).
Methods: A total of 399 participants consisting of 133 pregnant women diagnosed with PE and 266 healthy pregnant controls were included in the study. Data collected included demographic and obstetric history, gestational age at diagnosis, maternal hematological and biochemical parameters, first trimester neutrophil/albumin ratio (NAR) and NPAR values, and neonatal outcomes.
Results: The pre-eclampsia group showed significantly higher NAR (mean: 312.30, range: 80.00-1568.00) and NPAR (mean: 3.14 ± 0.81) compared to the control group (mean NAR: 234.40, range: 78.16-725.00; mean NPAR: 2.06 ± 0.38; p = 0.001 for both). Furthermore, early-onset PE was associated with significantly higher NAR (395.00 vs. 256.23, p = 0.001) and NPAR (3.87 vs. 2.80, p = 0.001) compared to late-onset PE. For early-onset PE, NPAR showed a sensitivity of 76.19%, specificity of 92.31%, PPV of 82.05%, NPV of 89.36% and area under the curve (AUC) of 0.897, demonstrating its strong potential as an early predictor of pre-eclampsia.
Conclusion: NPAR is elevated in PE compared to healthy pregnancies, demonstrating its potential as a simple yet effective biomarker for predicting PE.
{"title":"First-trimester neutrophil percentage-to-albumin ratio: a novel predictor for preeclampsia.","authors":"Çağlayan Biçer, Fatih Akkuş, Yusuf Dal","doi":"10.1080/17520363.2025.2511468","DOIUrl":"10.1080/17520363.2025.2511468","url":null,"abstract":"<p><strong>Objective: </strong>This retrospective study evaluated the predictive power of a new marker for pre-eclampsia (PE), the neutrophil percentage/albumin ratio (NPAR).</p><p><strong>Methods: </strong>A total of 399 participants consisting of 133 pregnant women diagnosed with PE and 266 healthy pregnant controls were included in the study. Data collected included demographic and obstetric history, gestational age at diagnosis, maternal hematological and biochemical parameters, first trimester neutrophil/albumin ratio (NAR) and NPAR values, and neonatal outcomes.</p><p><strong>Results: </strong>The pre-eclampsia group showed significantly higher NAR (mean: 312.30, range: 80.00-1568.00) and NPAR (mean: 3.14 ± 0.81) compared to the control group (mean NAR: 234.40, range: 78.16-725.00; mean NPAR: 2.06 ± 0.38; <i>p</i> = 0.001 for both). Furthermore, early-onset PE was associated with significantly higher NAR (395.00 vs. 256.23, <i>p</i> = 0.001) and NPAR (3.87 vs. 2.80, <i>p</i> = 0.001) compared to late-onset PE. For early-onset PE, NPAR showed a sensitivity of 76.19%, specificity of 92.31%, PPV of 82.05%, NPV of 89.36% and area under the curve (AUC) of 0.897, demonstrating its strong potential as an early predictor of pre-eclampsia.</p><p><strong>Conclusion: </strong>NPAR is elevated in PE compared to healthy pregnancies, demonstrating its potential as a simple yet effective biomarker for predicting PE.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"415-423"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140476/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144141461","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-06-12DOI: 10.1080/17520363.2025.2517524
Osman Uzman, Murat Bastopcu, Mehmet Saygı, Koray Kalenderoğlu, Koray Demir, Kıvanç Keskin, Sait Terzi
Background: This study assesses the influence of early hyperlactatemia after the transcatheter aortic valve implantation (TAVI) procedure on subsequent outcomes.
Methods: Adult patients undergoing elective percutaneous TAVI between 2012 and 2022 in a single tertiary cardiac center were retrospectively included. Peak post-procedure lactate level within 24-h was recorded for 284 patients included in the study. The primary outcome measured was 30-day mortality.
Results: 19 patients (6.6%) experienced 30-day mortality. Patients with mortality were characterized by advanced age (p = 0.022) and higher lactate levels after the procedure (5.4 ± 5.4 mmol/L vs 1.3 ± 0.6 mmol/L, p < 0.001). Post-procedure hyperlactatemia was an independent predictor of mortality (OR 3.95, 95% CI 1.35-11.60, p = 0.012). ROC analysis revealed 1.54 mmol/L as a cutoff for mortality with 85.7% specificity and 68.4% sensitivity.
Conclusion: The initial 24-hour lactate levels seem to play a valuable role in predicting the likelihood of surviving during the hospital stay after the implantation procedure. Further investigation is required to ascertain the optimal strategies for managing early post-procedure hyperlactatemia in the TAVI population.
背景:本研究评估经导管主动脉瓣植入术(TAVI)后早期高乳酸血症对后续预后的影响。方法:回顾性分析2012年至2022年在单一三级心脏中心接受选择性经皮TAVI的成年患者。研究中记录了284例患者术后24小时内乳酸水平的峰值。测量的主要结局是30天死亡率。结果:19例患者(6.6%)30天死亡。患者死亡率以高龄(p = 0.022)和术后乳酸水平增高(5.4±5.4 mmol/L vs 1.3±0.6 mmol/L, p = 0.012)为特征。ROC分析显示1.54 mmol/L为死亡率的临界值,特异性为85.7%,敏感性为68.4%。结论:最初24小时乳酸水平似乎在预测植入手术后住院期间存活的可能性方面发挥了重要作用。需要进一步的研究来确定治疗TAVI人群术后早期高乳酸血症的最佳策略。
{"title":"The relationship of serum lactate level with in-hospital mortality after transcatheter aortic valve implantation.","authors":"Osman Uzman, Murat Bastopcu, Mehmet Saygı, Koray Kalenderoğlu, Koray Demir, Kıvanç Keskin, Sait Terzi","doi":"10.1080/17520363.2025.2517524","DOIUrl":"10.1080/17520363.2025.2517524","url":null,"abstract":"<p><strong>Background: </strong>This study assesses the influence of early hyperlactatemia after the transcatheter aortic valve implantation (TAVI) procedure on subsequent outcomes.</p><p><strong>Methods: </strong>Adult patients undergoing elective percutaneous TAVI between 2012 and 2022 in a single tertiary cardiac center were retrospectively included. Peak post-procedure lactate level within 24-h was recorded for 284 patients included in the study. The primary outcome measured was 30-day mortality.</p><p><strong>Results: </strong>19 patients (6.6%) experienced 30-day mortality. Patients with mortality were characterized by advanced age (<i>p</i> = 0.022) and higher lactate levels after the procedure (5.4 ± 5.4 mmol/L vs 1.3 ± 0.6 mmol/L, <i>p</i> < 0.001). Post-procedure hyperlactatemia was an independent predictor of mortality (OR 3.95, 95% CI 1.35-11.60, <i>p</i> = 0.012). ROC analysis revealed 1.54 mmol/L as a cutoff for mortality with 85.7% specificity and 68.4% sensitivity.</p><p><strong>Conclusion: </strong>The initial 24-hour lactate levels seem to play a valuable role in predicting the likelihood of surviving during the hospital stay after the implantation procedure. Further investigation is required to ascertain the optimal strategies for managing early post-procedure hyperlactatemia in the TAVI population.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"481-489"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184198/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-06-16DOI: 10.1080/17520363.2025.2520738
Bin Wang, Xie Zheng, Qinghui Fu, Xiaoqian Luo, Sijun Pan
Background: Type 2 CRS is characterized by the development of renal dysfunction secondary to chronic cardiac disease. Despite its high morbidity and mortality, there is a lack of robust diagnostic tools and prognostic models to guide clinical management.
Methods: This multicenter retrospective study included patients diagnosed with CRS type 2 based on the 2019 American Heart Association definition. Data were collected from electronic medical records of three hospitals between January 2021 and December 2023. Advanced statistical methods, including receiver operating characteristic (ROC) curve analysis, univariate Kaplan-Meier (KM) analysis, and multivariable Cox proportional hazards regression, were utilized to develop a nomogram for predicting patient prognosis.
Results: The study included 519 patients with CRS-2. Independent predictors of adverse outcomes included elevated serum creatinine and blood urea nitrogen (BUN) levels, decreased platelet count, elevated B-type natriuretic peptide (BNP), and decreased oxygen partial pressure (PaO2). These findings suggest that close monitoring of these markers is essential in clinical practice to identify patients at high risk of adverse events early on.
Conclusion: Our study provides evidence that serum creatinine, BUN, platelet count, BNP, and PaO2 are independent predictors of adverse outcomes in patients with Type 2 CRS.
{"title":"Predictor and prognostic modeling in cardiorenal syndrome type 2: a retrospective study of multicenter.","authors":"Bin Wang, Xie Zheng, Qinghui Fu, Xiaoqian Luo, Sijun Pan","doi":"10.1080/17520363.2025.2520738","DOIUrl":"10.1080/17520363.2025.2520738","url":null,"abstract":"<p><strong>Background: </strong>Type 2 CRS is characterized by the development of renal dysfunction secondary to chronic cardiac disease. Despite its high morbidity and mortality, there is a lack of robust diagnostic tools and prognostic models to guide clinical management.</p><p><strong>Methods: </strong>This multicenter retrospective study included patients diagnosed with CRS type 2 based on the 2019 American Heart Association definition. Data were collected from electronic medical records of three hospitals between January 2021 and December 2023. Advanced statistical methods, including receiver operating characteristic (ROC) curve analysis, univariate Kaplan-Meier (KM) analysis, and multivariable Cox proportional hazards regression, were utilized to develop a nomogram for predicting patient prognosis.</p><p><strong>Results: </strong>The study included 519 patients with CRS-2. Independent predictors of adverse outcomes included elevated serum creatinine and blood urea nitrogen (BUN) levels, decreased platelet count, elevated B-type natriuretic peptide (BNP), and decreased oxygen partial pressure (PaO2). These findings suggest that close monitoring of these markers is essential in clinical practice to identify patients at high risk of adverse events early on.</p><p><strong>Conclusion: </strong>Our study provides evidence that serum creatinine, BUN, platelet count, BNP, and PaO2 are independent predictors of adverse outcomes in patients with Type 2 CRS.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"491-499"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184174/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144301150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-05-19DOI: 10.1080/17520363.2025.2508136
Francesca Casarin, Ruggiero Mascolo, Antonio Brucato
{"title":"Letter to the editor on the article \"Clinical relevance of HRR and RAR in pericarditis\" by Hatice Eyiol et al.","authors":"Francesca Casarin, Ruggiero Mascolo, Antonio Brucato","doi":"10.1080/17520363.2025.2508136","DOIUrl":"10.1080/17520363.2025.2508136","url":null,"abstract":"","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"393-394"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12140458/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144092551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-06-08DOI: 10.1080/17520363.2025.2517525
Ashok Kumar Pannu
{"title":"Expanding risk stratification in acute coronary syndromes with systemic indices: HALP and CALLY.","authors":"Ashok Kumar Pannu","doi":"10.1080/17520363.2025.2517525","DOIUrl":"10.1080/17520363.2025.2517525","url":null,"abstract":"","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"451-453"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184129/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246440","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Background: This study assessed serum GP73, Nrf2, and CHE levels in pregnancy-associated liver injury and explored their nonlinear risk relationships using restricted cubic spline (RCS) models to establish diagnostic thresholds for early screening.
Methods: Conducted from December 2022 to December 2024, 105 pregnant women with liver injury (research group) and 187 healthy controls were retrospectively analyzed. Multivariate logistic regression, ROC curves, RCS models, and decision curve analysis (DCA) evaluated associations, predictive efficacy, dose-response relationships, and clinical utility of these biomarkers.
Results: Elevated GP73 and Nrf2, multiple pregnancies, antipyretic/anti-infective medication use, and malnutrition were risk factors (p < 0.05), while high CHE was protective (p < 0.05). ROC analysis showed AUCs of 0.801 (GP73), 0.785 (Nrf2), and 0.726 (CHE) combined AUC reached 0.951. RCS revealed nonlinear dose-response relationships (p < 0.001), and DCA confirmed clinical significance (net benefit > 0) for individual and combined biomarkers, with the panel showing the highest utility.
Conclusion: GP73, Nrf2, and CHE demonstrated nonlinear associations with pregnancy-related liver injury, particularly GP73. Combined measurement enhances clinical value for early prediction.
背景:本研究评估了妊娠相关肝损伤患者血清GP73、Nrf2和CHE水平,并利用限制性三次样条(RCS)模型探讨了它们之间的非线性风险关系,以建立早期筛查的诊断阈值。方法:对2022年12月~ 2024年12月105例肝损伤孕妇(研究组)和187例健康对照进行回顾性分析。多变量logistic回归、ROC曲线、RCS模型和决策曲线分析(DCA)评估了这些生物标志物的相关性、预测功效、剂量-反应关系和临床应用。结果:GP73和Nrf2升高、多胎妊娠、退热/抗感染药物使用和营养不良是个体和联合生物标志物的危险因素(p p p 0),面板显示出最高的效用。结论:GP73、Nrf2和CHE与妊娠相关性肝损伤呈非线性相关,尤其是GP73。联合测量提高了早期预测的临床价值。
{"title":"Serum GP73, Nrf2, CHE in early pregnancy-related liver injury detection via RCS model.","authors":"Deng Huang, Yanjun Hu, Biwen Dong, Zhi Zheng, Hai Wang, Tingting Liao, Wenhan Wang, Xianjue Zheng, Zitong Xu, Shuqi Xia, Xiaoqing Li, Congcong Sun, Hongping Zhang, Jiayong Zheng","doi":"10.1080/17520363.2025.2516998","DOIUrl":"10.1080/17520363.2025.2516998","url":null,"abstract":"<p><strong>Background: </strong>This study assessed serum GP73, Nrf2, and CHE levels in pregnancy-associated liver injury and explored their nonlinear risk relationships using restricted cubic spline (RCS) models to establish diagnostic thresholds for early screening.</p><p><strong>Methods: </strong>Conducted from December 2022 to December 2024, 105 pregnant women with liver injury (research group) and 187 healthy controls were retrospectively analyzed. Multivariate logistic regression, ROC curves, RCS models, and decision curve analysis (DCA) evaluated associations, predictive efficacy, dose-response relationships, and clinical utility of these biomarkers.</p><p><strong>Results: </strong>Elevated GP73 and Nrf2, multiple pregnancies, antipyretic/anti-infective medication use, and malnutrition were risk factors (<i>p</i> < 0.05), while high CHE was protective (<i>p</i> < 0.05). ROC analysis showed AUCs of 0.801 (GP73), 0.785 (Nrf2), and 0.726 (CHE) combined AUC reached 0.951. RCS revealed nonlinear dose-response relationships (<i>p</i> < 0.001), and DCA confirmed clinical significance (net benefit > 0) for individual and combined biomarkers, with the panel showing the highest utility.</p><p><strong>Conclusion: </strong>GP73, Nrf2, and CHE demonstrated nonlinear associations with pregnancy-related liver injury, particularly GP73. Combined measurement enhances clinical value for early prediction.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"455-462"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184170/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246441","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2025-06-01Epub Date: 2025-05-06DOI: 10.1080/17520363.2025.2501925
Hou Xu, Xiaohong Jiang, Zhiheng Liu, Xueli Zhang, Guijie Liu, Yanchao Gao, Wei Zhang, Jun Liu
Introduction: We investigated the potential correlation between abnormal blood glucose on admission and clinical outcomes of acute calculus cholecystitis in older patients.
Areas covered: We included older patients (≥65 years) diagnosed with acute calculus cholecystitis. The first plasma glucose measurement obtained at admission was used. Overall, 280 older patients were evaluated. The results showed that ABG was significantly associated with more severe systemic inflammatory responses (elevated white blood cell count and neutrophil-lymphocyte ratio), a higher incidence of moderate to severe ACC, and the need for invasive treatment (an increased proportion of percutaneous cholecystostomy and combined surgeries). The prolonged hospital stay, 30-day readmission rate and mortality rate of patients in the ABG group were significantly increased, and the incidence of severe postoperative complications (Clavien-Dindo≥grade III) was higher. Multivariate analysis confirmed that ABG was an independent predictor of the severity of ACC (TG18 classification) and 30-day re-admission rate.
Expert opinion/commentary: In older patients with acute calculus cholecystitis, abnormal blood glucose on admission is associated with worse outcomes, serving as a novel quantifiable risk criterion to guide treatment selection, particularly for high-risk older adults ineligible for early surgery.
{"title":"Abnormal blood glucose on admission and outcomes in older patients with acute calculous cholecystitis.","authors":"Hou Xu, Xiaohong Jiang, Zhiheng Liu, Xueli Zhang, Guijie Liu, Yanchao Gao, Wei Zhang, Jun Liu","doi":"10.1080/17520363.2025.2501925","DOIUrl":"10.1080/17520363.2025.2501925","url":null,"abstract":"<p><strong>Introduction: </strong>We investigated the potential correlation between abnormal blood glucose on admission and clinical outcomes of acute calculus cholecystitis in older patients.</p><p><strong>Areas covered: </strong>We included older patients (≥65 years) diagnosed with acute calculus cholecystitis. The first plasma glucose measurement obtained at admission was used. Overall, 280 older patients were evaluated. The results showed that ABG was significantly associated with more severe systemic inflammatory responses (elevated white blood cell count and neutrophil-lymphocyte ratio), a higher incidence of moderate to severe ACC, and the need for invasive treatment (an increased proportion of percutaneous cholecystostomy and combined surgeries). The prolonged hospital stay, 30-day readmission rate and mortality rate of patients in the ABG group were significantly increased, and the incidence of severe postoperative complications (Clavien-Dindo≥grade III) was higher. Multivariate analysis confirmed that ABG was an independent predictor of the severity of ACC (TG18 classification) and 30-day re-admission rate.</p><p><strong>Expert opinion/commentary: </strong>In older patients with acute calculus cholecystitis, abnormal blood glucose on admission is associated with worse outcomes, serving as a novel quantifiable risk criterion to guide treatment selection, particularly for high-risk older adults ineligible for early surgery.</p>","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"405-414"},"PeriodicalIF":1.9,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12143728/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143953720","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}